date,text,form,accepted_time
2020-06-09," 8-k 1 ea122844-8k_charden.htm form 8-k united states securities and exchange commission washington, d.c. 20549 form 8-k current report pursuant to section 13 or 15(d) of the securities exchange act of 1934 june 5, 2020 date of report (date of earliest event reported) chardan healthcare acquisition 2 corp (exact name of registrant as specified in its charter) delaware 001-39271 83-3169838 (state or other jurisdiction of incorporation) (commission file number) (i.r.s. employer identification no.) 17 state street, 21st floor new york, ny 10004 (address of principal executive offices) (zip code) registrant’s telephone number, including area code: (646) 465-9000 n/a (former name or former address, if changed since last report) check the appropriate box below if the form 8-k filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ¨ written communications pursuant to rule 425 under the securities act ¨ soliciting material pursuant to rule 14a-12 under the exchange act ¨ pre-commencement communications pursuant to rule 14d-2(b) under the exchange act ¨ pre-commencement communications pursuant to rule 13e-4(c) under the exchange act securities registered pursuant to section 12(b) of the act: title of each class trading symbol(s) name of each exchange on which registered common stock chaq nyse american, llc warrants chaqw nyse american, llc units chaqu nyse american, llc indicate by check mark whether the registrant is an emerging growth company as defined in rule 405 of the securities act of 1933 (17 cfr §230.405) or rule 12b-2 of the securities exchange act of 1934 (17 cfr §240.12b-2). emerging growth company x if an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the exchange act. ¨ item 3.02. unregistered sales of equity securities. the information included in item 8.01 is incorporated into this item by reference. item 8.01. other events as previously disclosed on a current report on form 8-k dated april 23, 2020, chardan healthcare acquisition 2 corp. (the “company”), consummated its initial public offering (“ipo”) of 8,500,000 units (the “units”). each unit consists of one share of common stock, $0.0001 par value (“common stock”), and one warrant (“warrant”) entitling its holder to purchase one-half of one share of common stock at a price of $11.50 per whole share. the units were sold at an offering price of $10.00 per unit, generating gross proceeds of $85,000,000. the company granted the underwriters a 45-day option to purchase up to 1,275,000 additional units to cover over-allotments, if any. as also previously disclosed in the current report, simultaneously with the closing of the ipo, the company consummated the private placement (“private placement”) with chardan investments 2, llc of 3,500,000 warrants (the “private warrants”) to purchase 3,500,000 shares of common stock, each at a price of $0.40 per private warrant, generating total proceeds of $1,400,000. subsequently, on june 4, 2020, the underwriters exercised the over-allotment option in part, and the closing of the issuance and sale of the additional units occurred (the “over-allotment option units”) on june 5, 2020. the total aggregate issuance by the company of 122,644 units at a price of $10.00 per unit resulted in total gross proceeds of $1,226,440. on june 5, 2020, the underwriters canceled the remainder of the over-allotment option. in connection with the cancellation of the remainder of the over-allotment option, the company has canceled an aggregate of 288,089 shares of common stock issued to certain stockholder of the company prior to the ipo and private placement. a total of $86,226,440 of the net proceeds from the sale of units in the initial public offering (including the over-allotment option units) and the private placement on april 28, 2020, were placed in a trust account established for the benefit of the company’s public shareholders. included with this report as exhibit 99.1 is a pro-forma balance sheet reflecting the exercise of the over-allotment option. item 9.01. financial statements and exhibits. exhibit no. description 99.1 balance sheet dated april 28, 2020 2 signatures pursuant to the requirements of the securities exchange act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. dated: june 9, 2020 chardan healthcare acquisition 2 corp. by: /s/ jonas grossman name: jonas grossman title: chief executive officer 3 ",8-K,2020-06-09 16:45:35
2020-05-04," 8-k 1 ea121272-8k_chardanhealth.htm current report united states securities and exchange commission washington, d.c. 20549 form 8-k current report pursuant to section 13 or 15(d) of the securities exchange act of 1934 april 28, 2020 date of report (date of earliest event reported) chardan healthcare acquisition 2 corp. (exact name of registrant as specified in its charter) delaware 001-39271 83-3169838 (state or other jurisdiction of incorporation) (commission file number) (i.r.s. employer identification no.) 17 state street, 21st floor new york, ny 10004 (address of principal executive offices) (zip code) registrant’s telephone number, including area code: (646) 465-9000 n/a (former name or former address, if changed since last report) check the appropriate box below if the form 8-k filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐written communications pursuant to rule 425 under the securities act ☐soliciting material pursuant to rule 14a-12 under the exchange act ☐pre-commencement communications pursuant to rule 14d-2(b) under the exchange act ☐pre-commencement communications pursuant to rule 13e-4(c) under the exchange act securities registered pursuant to section 12(b) of the act: title of each class trading symbol(s) name of each exchange on which registered common stock chaq nyse american, llc warrants chaqw nyse american, llc units chaqu nyse american, llc indicate by check mark whether the registrant is an emerging growth company as defined in rule 405 of the securities act of 1933 (17 cfr §230.405) or rule 12b-2 of the securities exchange act of 1934 (17 cfr §240.12b-2). emerging growth company ☒ if an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the exchange act. ☐ item 8.01. other events as previously disclosed on a current report on form 8-k dated april 23, 2020, on april 28, 2020 chardan healthcare acquisition 2 corp. (the “company”) consummated the ipo of 8,500,000 units (the “units”). each unit consists of one share of common stock (“common stock”) and one warrant (“warrant”) entitling its holder to purchase one-half share of common stock at a price of $11.50 per whole share. the units were sold at an offering price of $10.00 per unit, generating gross proceeds of $85,000,000. as of april 28, 2020, a total of $85,000,000 of the net proceeds from the ipo and the private placement consummated simultaneously with the closing of the ipo were deposited in a trust account established for the benefit of the company’s public stockholders. an audited balance sheet as of april 28, 2020 reflecting receipt of the proceeds upon consummation of the ipo and the private placement is included with this report as exhibit 99.1 item 9.01. financial statements and exhibits. exhibit no. description 99.1 balance sheet dated april 28, 2020 1 signatures pursuant to the requirements of the securities exchange act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. dated: may 4, 2020 chardan healthcare acquisition 2 corp. by: /s/ jonas grossman name: jonas grossman title: chief executive officer 2 ",8-K,2020-05-04 17:00:18
2020-04-29," 8-k 1 ea121108-8k_chardanhealth.htm current report united states securities and exchange commission washington, d.c. 20549 form 8-k current report pursuant to section 13 or 15(d) of the securities exchange act of 1934 april 23, 2020 date of report (date of earliest event reported) chardan healthcare acquisition 2 corp. (exact name of registrant as specified in its charter) delaware 001-39271 83-3169838 (state or other jurisdiction of incorporation) (commission file number) (i.r.s. employer identification no.) 17 state street, 21st floor new york, ny 10004 (address of principal executive offices) (zip code) registrant’s telephone number, including area code: (646) 465-9000 n/a (former name or former address, if changed since last report) check the appropriate box below if the form 8-k filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐written communications pursuant to rule 425 under the securities act ☐soliciting material pursuant to rule 14a-12 under the exchange act ☐pre-commencement communications pursuant to rule 14d-2(b) under the exchange act ☐pre-commencement communications pursuant to rule 13e-4(c) under the exchange act securities registered pursuant to section 12(b) of the act: title of each class trading symbol(s) name of each exchange on which registered common stock chaq nyse american, llc warrants chaq.w nyse american, llc units chaq.u nyse american, llc indicate by check mark whether the registrant is an emerging growth company as defined in rule 405 of the securities act of 1933 (17 cfr §230.405) or rule 12b-2 of the securities exchange act of 1934 (17 cfr §240.12b-2). emerging growth company ☒ if an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the exchange act. ☐ item 1.01. entry into a material definitive agreement. on april 23, 2020, the registration statement (file no. 333-236977) (the “registration statement”) relating to the initial public offering (“ipo”) of chardan healthcare acquisition 2 corp.(the “company”) was declared effective by the securities and exchange commission. in connection therewith, the company entered into the following agreements previously filed as exhibits to the registration statement: ● an underwriting agreement, dated april 23, 2020, by and between the company and chardan capital markets, llc (“chardan”), as representative of the underwriters; ● a warrant agreement, dated april 23, 2020, by and between the company and continental stock transfer & trust company; ● letter agreements, dated april 23, 2020, by and between the company’s officers, directors and shareholders; ● an investment management trust agreement, dated april 23, 2020, by and between continental stock transfer & trust company and the company; ● an escrow agreement, dated april 23, 2020, by and among the company, continental stock transfer & trust company and each of the initial shareholders of the company; and ● indemnity agreements, dated april 23, 2020, by and among the company and the directors and officers of the company; ● a subscription agreement, dated april 23, 2020, by and between the company and chardan investments 2, llc; ● a registration rights agreement, dated april 23, 2020, by and among the company and the initial shareholders of the company; and ● a promissory note, dated april 28, 2020, by and among the company and chardan investments 2, llc on april 28, 2020, the company consummated the ipo of 8,500,000 units (the “units”). each unit consists of one share of common stock, $0.0001 par value (“common stock”), and one warrant (“warrant”) entitling its holder to purchase one-half of one share of common stock at a price of $11.50 per whole share. the units were sold at an offering price of $10.00 per unit, generating gross proceeds of $85,000,000. the company granted the underwriters a 45-day option to purchase up to 1,275,000 additional units to cover over-allotments, if any. as of april 28, 2020, a total of $85,000,000 of the net proceeds from the ipo and the private placement (as defined below) were deposited in a trust account established for the benefit of the company’s public shareholders. an audited balance sheet as of april 28, 2020 reflecting receipt of the proceeds upon consummation of the ipo and the private placement will be filed within 4 business days of the consummation of the ipo. item 2.03 creation of a direct financial obligation or an obligation under an off-balance sheet arrangement of registrant. on april 28, 2020, the company issued an unsecured promissory note in the aggregate principal amount of $500,000 (the “note”) to chardan investments 2, llc. the note does not bear interest and matures upon closing of a business combination by the company. item 3.02. unregistered sales of equity securities. simultaneously with the closing of the ipo, the company consummated the private placement (“private placement”) with chardan investments 2, llc of 3,500,000 warrants (the “private warrants”) to purchase 3,500,000 shares of common stock, each at a price of $0.40 per private warrant, generating total proceeds of $1,400,000. the private warrants are identical to the warrants sold in the ipo except that each private warrant is exercisable for one share of common stock at an exercise price of $11.50 per share, and the private warrants will be non-redeemable and may be exercised on a cashless basis, in each case so long as they continue to be held by the initial purchasers or their permitted transferees. additionally, such initial purchasers agreed not to transfer, assign or sell any of the private warrants or underlying securities (except in limited circumstances, as described in the registration statement) until the completion of the company’s initial business combination. such initial purchasers were granted certain demand and piggyback registration rights in connection with the purchase of the private warrants. the private warrants were issued pursuant to section 4(a)(2) of the securities act of 1933, as amended, as the transactions did not involve a public offering. item 5.03. amendments to certificate of incorporation or bylaws; change in fiscal year. on april 23, 2020, in connection with the ipo, the company filed its amended and restated certificate of incorporation with the delaware secretary of state. the terms of the amended and restated certificate of incorporation are set forth in the registration statement and are incorporated herein by reference. 1 item 9.01. financial statements and exhibits. exhibit no. description 1.1 underwriting agreement, dated april 23, 2020, by and between the company and chardan capital markets, llc. 3.1 amended and restated certificate of incorporation. 4.1 warrant agreement, dated april 23, 2020, by and between continental stock transfer & trust company and the company. 10.1 letter agreements, dated april 23, 2020, among the registrant and the company’s officers, directors and initial stockholders. 10.2 investment management trust agreement, dated april 23, 2020, by and between continental stock transfer & trust company and the company. 10.3 stock escrow agreement, dated april 23, 2020, among the registrant, continental stock transfer & trust company and the initial stockholders. 10.4 registration rights agreement, dated april 23, 2020, by and between the registrant and initial stockholders. 10.5 promissory note, dated april 28, 2020, by and between the registrant and chardan investments 2, llc 10.6 indemnity agreements, dated april 23, 2020, by and among the registrant and the directors and officers of the registrant 10.7 subscription agreement, dated april 23, 2020, by and between the registrant and chardan investments 2, llc 2 signatures pursuant to the requirements of the securities exchange act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. dated: april 29, 2020 chardan healthcare acquisition 2 corp. by: /s/ jonas grossman name: jonas grossman title: chief executive officer 3 ",8-K,2020-04-29 15:04:07
